Compare Danaher Corporation (DHR) vs Payoneer Global Inc (PAYO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Payoneer Global Inc — how do they compare? Danaher Corporation trades at $207.45 (market cap $145.83B), while Payoneer Global Inc trades at $7.13 (market cap $2.40B). The key difference: Danaher Corporation is far larger — about 60.8× Payoneer Global Inc's market cap, and Danaher Corporation pays a 0.77% dividend while Payoneer Global Inc pays none. Which is the better fit depends on your goals.
| DHR | PAYO | |
|---|---|---|
Market Cap | $145.83B | $2.40B |
Sector | Health | Technology |
52-Week High | $242.05 | $7.17 |
52-Week Low | $161.91 | $4.27 |
Enterprise Value | $168.04B | $2.14B |
Dividend Yield | 0.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $209.26, up 2.2% today, with strong technical momentum as the price sits above key support levels. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.92. Fundamentals show robust profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst sentiment is overwhelmingly positive with 69% buy ratings and a $202.33 consensus price target. Recent news highlights the acquisition of Masimo and new product launches in its biotechnology segment.
The outlook for DHR remains favorable driven by earnings beats and strategic acquisitions, but investors face risks from elevated valuation multiples and potential macroeconomic headwinds. The stock's current technical overbought condition suggests near-term consolidation may occur, yet long-term growth prospects in life sciences support a bullish stance. Key watch points include Q3 2026 earnings results and integration progress of recent acquisitions.
PAYO trades at $7.095, up 0.07% today, near its 52-week high of $7.67. The stock shows a bullish technical signal with moving averages supporting upside, while oscillators are neutral. Recent Q2 2026 earnings missed estimates at $0.02 per share versus $0.06 expected, though revenue grew 10% year-over-year. The pending acquisition by Nuvei for $7.40 per share, announced June 15, 2026, anchors the price near deal terms, with legal inquiries ongoing regarding fairness.
Outlook is acquisition-driven with limited upside to the $7.40 offer, posing a 4.3% gain from current levels. Risks include deal completion uncertainty and earnings volatility, while opportunities lie in potential bid revisions. Analysts maintain a 60% buy rating with an $8.20 consensus target, suggesting confidence in long-term value beyond the takeover.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Payoneer Global Inc
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →
